These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 30600675)

  • 1. Stem Cell Markers Predict the Response to Sorafenib in Patients with Hepatocellular Carcinoma.
    Kim BH; Park JW; Kim JS; Lee SK; Hong EK
    Gut Liver; 2019 May; 13(3):342-348. PubMed ID: 30600675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a unique hepatocellular carcinoma line, Li-7, with CD13(+) cancer stem cells hierarchy and population change upon its differentiation during culture and effects of sorafenib.
    Yamada T; Abei M; Danjoh I; Shirota R; Yamashita T; Hyodo I; Nakamura Y
    BMC Cancer; 2015 Apr; 15():260. PubMed ID: 25885470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.
    Li M; Zhang L; Ge C; Chen L; Fang T; Li H; Tian H; Liu J; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J
    Oncotarget; 2015 Sep; 6(28):25149-60. PubMed ID: 26327240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib.
    Oh CR; Kong SY; Im HS; Kim HJ; Kim MK; Yoon KA; Cho EH; Jang JH; Lee J; Kang J; Park SR; Ryoo BY
    BMC Cancer; 2019 Apr; 19(1):292. PubMed ID: 30935424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor and cancer stem cells in hepatitis C virus-associated liver disease.
    Bahnassy AA; Zekri AR; El-Bastawisy A; Fawzy A; Shetta M; Hussein N; Omran D; Ahmed AA; El-Labbody SS
    World J Gastroenterol; 2014 Dec; 20(48):18240-8. PubMed ID: 25561791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALDH1A1-overexpressing cells are differentiated cells but not cancer stem or progenitor cells in human hepatocellular carcinoma.
    Tanaka K; Tomita H; Hisamatsu K; Nakashima T; Hatano Y; Sasaki Y; Osada S; Tanaka T; Miyazaki T; Yoshida K; Hara A
    Oncotarget; 2015 Sep; 6(28):24722-32. PubMed ID: 26160842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma.
    Guo Z; Li LQ; Jiang JH; Ou C; Zeng LX; Xiang BD
    World J Gastroenterol; 2014 Feb; 20(8):2098-106. PubMed ID: 24616575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in the neutrophil-to-lymphocyte ratio predict the prognosis of patients with advanced hepatocellular carcinoma treated with sorafenib.
    Hong YM; Yoon KT; Hwang TH; Heo J; Woo HY; Cho M
    Eur J Gastroenterol Hepatol; 2019 Oct; 31(10):1250-1255. PubMed ID: 30925530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
    Marisi G; Cucchetti A; Ulivi P; Canale M; Cabibbo G; Solaini L; Foschi FG; De Matteis S; Ercolani G; Valgiusti M; Frassineti GL; Scartozzi M; Casadei Gardini A
    World J Gastroenterol; 2018 Sep; 24(36):4152-4163. PubMed ID: 30271080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data.
    Bahnassy AA; Fawzy M; El-Wakil M; Zekri AR; Abdel-Sayed A; Sheta M
    Transl Res; 2015 Mar; 165(3):396-406. PubMed ID: 25168019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-589-5p inhibits MAP3K8 and suppresses CD90
    Zhang X; Jiang P; Shuai L; Chen K; Li Z; Zhang Y; Jiang Y; Li X
    J Exp Clin Cancer Res; 2016 Nov; 35(1):176. PubMed ID: 27835990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early decrease in serum amphiregulin or vascular endothelial growth factor levels predicts sorafenib efficacy in hepatocellular carcinoma.
    Godin C; Bodeau S; Saidak Z; Louandre C; François C; Barbare JC; Coriat R; Galmiche A; Sauzay C
    Oncol Rep; 2019 Mar; 41(3):2041-2050. PubMed ID: 30569112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
    De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
    World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of PRRX1 Confers Cancer Stem Cell-Like Properties and Predicts Poor Prognosis in Hepatocellular Carcinoma.
    Hirata H; Sugimachi K; Takahashi Y; Ueda M; Sakimura S; Uchi R; Kurashige J; Takano Y; Nanbara S; Komatsu H; Saito T; Shinden Y; Iguchi T; Eguchi H; Atsumi K; Sakamoto K; Doi T; Hirakawa M; Honda H; Mimori K
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1402-9. PubMed ID: 25404478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of the expression of cancer stem cell-related markers CD133 and CD44 in hepatocellular carcinoma: From patients to patient-derived tumor xenograft models.
    Zhao Q; Zhou H; Liu Q; Cao Y; Wang G; Hu A; Ruan L; Wang S; Bo Q; Chen W; Hu C; Xu D; Tao F; Cao J; Ge Y; Yu Z; Li L; Wang H
    Oncotarget; 2016 Jul; 7(30):47431-47443. PubMed ID: 27329727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
    Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
    Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib suppresses extrahepatic metastasis de novo in hepatocellular carcinoma through inhibition of mesenchymal cancer stem cells characterized by the expression of CD90.
    Yoshida M; Yamashita T; Okada H; Oishi N; Nio K; Hayashi T; Nomura Y; Hayashi T; Asahina Y; Ohwada M; Sunagozaka H; Takatori H; Colombo F; Porretti L; Honda M; Kaneko S
    Sci Rep; 2017 Sep; 7(1):11292. PubMed ID: 28900199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mRNA Distribution of Cancer Stem Cell Marker CD90/Thy-1 Is Comparable in Hepatocellular Carcinoma of Eastern and Western Populations.
    Luong AB; Do HQ; Tarchi P; Bonazza D; Bottin C; Cabral LKD; Tran LDC; Doan TPT; Crocè LS; Pham HLT; Tiribelli C; Sukowati CHC
    Cells; 2020 Dec; 9(12):. PubMed ID: 33322687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long Noncoding RNA (lncRNA) Small Nucleolar RNA Host Gene 16 (SNHG16) Predicts Poor Prognosis and Sorafenib Resistance in Hepatocellular Carcinoma.
    Guo Z; Zhang J; Fan L; Liu J; Yu H; Li X; Sun G
    Med Sci Monit; 2019 Mar; 25():2079-2086. PubMed ID: 30893293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study.
    Lee S; Kim BK; Kim SU; Park SY; Kim JK; Lee HW; Park JY; Kim DY; Ahn SH; Tak WY; Kweon YO; Lee JI; Lee KS; Kim HJ; Han KH
    J Gastroenterol Hepatol; 2014; 29(7):1463-9. PubMed ID: 25273508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.